10
Mar
The article in brief:
Contingent consideration, especially earnouts, helped sustain M&A deal momentum in 2025 amid macroeconomic uncertainty.
Earnouts are expanding beyond the life sciences sector, with shorter performance periods and increasingly ambitious payout hurdles.
As deal structures become more customized, valuation methodologies are evolving to keep pace with growing complexity.
How 2025’s Market Cycle Influenced Earnout Activity
M&A deal activity in 2025 unfolded in two distinct phases. Early in the year, shifting trade policy, uneven macroeconomic data, and persistent inflation...